X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The series A financing will support advancement of the company’s portfolio of first-in-class antibody treatments, which offer unique potential to address fibrosis at varying stages of the disease, with two programs advancing into human studies in 2024.
Lead Product(s): Antibody
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Venture Fund
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 15, 2023
Details:
Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Lead Product(s): Neutralizing antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Distributed Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
